Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 13

1.

An antibody to IP-10 is a potent antagonist of cell migration in vitro and in vivo and does not affect disease in several animal models of inflammation.

Byrne FR, Winters A, Brankow D, Hu S, Juan T, Steavenson S, Doellgast G, Kuchimanchi K, Brown H, Anderson S, Smelt S, Sullivan T, Alcorn D, Tocker J, Dean C Jr, Macmaster J, Kirchner J, Buys J, Manoukian R, Jiao E, Zou X, Campanella GS, Siu G.

Autoimmunity. 2009 Mar;42(3):171-82. doi: 10.1080/08916930802629547.

PMID:
19301198
[PubMed - indexed for MEDLINE]
2.

T-cell immune response cDNA 7 in allograft rejection and inflammation.

Utku N, Heinemann T, Milford EL.

Curr Opin Investig Drugs. 2007 May;8(5):401-10. Review.

PMID:
17520869
[PubMed - indexed for MEDLINE]
3.

Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease.

Kanai T, Nemoto Y, Kamada N, Totsuka T, Hisamatsu T, Watanabe M, Hibi T.

Curr Opin Gastroenterol. 2009 Jul;25(4):306-13. doi: 10.1097/MOG.0b013e32832bc627. Review.

PMID:
19448533
[PubMed - indexed for MEDLINE]
4.

Monoclonal antibodies to CD4.

Breedveld FC.

Rheum Dis Clin North Am. 1998 Aug;24(3):567-78. Review.

PMID:
9710887
[PubMed - indexed for MEDLINE]
5.

Monoclonal antibodies in immune and inflammatory diseases.

Andreakos E, Taylor PC, Feldmann M.

Curr Opin Biotechnol. 2002 Dec;13(6):615-20. Review.

PMID:
12482523
[PubMed - indexed for MEDLINE]
6.

CXCL10 and autoimmune diseases.

Lee EY, Lee ZH, Song YW.

Autoimmun Rev. 2009 Mar;8(5):379-83. doi: 10.1016/j.autrev.2008.12.002. Epub 2008 Dec 25. Review.

PMID:
19105984
[PubMed - indexed for MEDLINE]
7.

CD44 involvement in autoimmune inflammations: the lesson to be learned from CD44-targeting by antibody or from knockout mice.

Naor D, Nedvetzki S, Walmsley M, Yayon A, Turley EA, Golan I, Caspi D, Sebban LE, Zick Y, Garin T, Karussis D, Assayag-Asherie N, Raz I, Weiss L, Slavin S, Golan I.

Ann N Y Acad Sci. 2007 Sep;1110:233-47. Review.

PMID:
17911438
[PubMed - indexed for MEDLINE]
8.

The use of chemokine antagonists in EAE models.

Proudfoot AE, de Souza AL, Muzio V.

J Neuroimmunol. 2008 Jul 31;198(1-2):27-30. doi: 10.1016/j.jneuroim.2008.04.007. Epub 2008 Jun 11. Review.

PMID:
18550179
[PubMed - indexed for MEDLINE]
9.

Challenges in monoclonal antibody-based therapies.

Samaranayake H, Wirth T, Schenkwein D, Räty JK, Ylä-Herttuala S.

Ann Med. 2009;41(5):322-31. doi: 10.1080/07853890802698842. Review.

PMID:
19234897
[PubMed - indexed for MEDLINE]
10.

Moving targets: cell migration inhibitors as new anti-inflammatory therapies.

Mackay CR.

Nat Immunol. 2008 Sep;9(9):988-98. doi: 10.1038/ni.f.210. Review.

PMID:
18711436
[PubMed - indexed for MEDLINE]
11.

Contributions of experimental mouse models to the understanding of African trypanosomiasis.

Antoine-Moussiaux N, Magez S, Desmecht D.

Trends Parasitol. 2008 Sep;24(9):411-8. doi: 10.1016/j.pt.2008.05.010. Epub 2008 Aug 4. Review.

PMID:
18684669
[PubMed - indexed for MEDLINE]
12.

Immunologic factors in transplant arteriopathy: insight from animal models.

Alexis JD, Pyo RT, Chereshnev I.

Mt Sinai J Med. 2003 May;70(3):191-6. Review.

PMID:
12764538
[PubMed - indexed for MEDLINE]
13.

Atypical chemokine receptors in inflammatory disease.

Patel M, McInnes IB, Graham G.

Curr Mol Med. 2009 Feb;9(1):86-93. Review.

PMID:
19199944
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk